Lupus Nephritis
Interventions of Interest: voclosporin (Lupkynis™, Aurinia Pharmaceuticals) belimumab (Benlysta®, GlaxoSmithKline) ICER is assessing the comparative clinical effectiveness and value of voclosporin (Lupkynis™, Aurinia Pharmaceuticals) and belimumab (Benlysta®, GlaxoSmithKline) for the treatment of lupus nephritis. Voclosporin was approved for lupus nephritis in 2021, and belimumab is seeking a label expansion for the treatment of lupus nephritis. […]